These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24652467)

  • 1. Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.
    Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
    JAMA Ophthalmol; 2014 May; 132(5):572-8. PubMed ID: 24652467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial.
    Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
    Ophthalmology; 2014 Oct; 121(10):1885-91. PubMed ID: 24953794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of orbital inflammation with rituximab in Wegener's granulomatosis.
    Baslund B; Wiencke AK; Rasmussen N; Faurschou M; Toft PB
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S7-10. PubMed ID: 22272561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.
    Burak KW; Swain MG; Santodomingo-Garzon T; Lee SS; Urbanski SJ; Aspinall AI; Coffin CS; Myers RP
    Can J Gastroenterol; 2013; 27(5):273-80. PubMed ID: 23712302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
    Cho HH; Jin SP; Chung JH
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.
    Ingen-Housz-Oro S; Valeyrie-Allanore L; Cosnes A; Ortonne N; Hüe S; Paul M; Wolkenstein P; Chosidow O
    JAMA Dermatol; 2015 Feb; 151(2):200-3. PubMed ID: 25354242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.
    Arce-Salinas CA; Rodríguez-García F; Gómez-Vargas JI
    Rheumatol Int; 2012 May; 32(5):1245-9. PubMed ID: 21258801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
    Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable remission of pemphigus with a fixed-dose rituximab protocol.
    Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
    JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients.
    Kim JH; Kim YH; Kim MR; Kim SC
    Br J Dermatol; 2011 Sep; 165(3):646-51. PubMed ID: 21574976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for thyroid eye disease.
    Silkiss RZ; Reier A; Coleman M; Lauer SA
    Ophthalmic Plast Reconstr Surg; 2010; 26(5):310-4. PubMed ID: 20562667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis.
    Miserocchi E; Modorati G; Berchicci L; Pontikaki I; Meroni P; Gerloni V
    Br J Ophthalmol; 2016 Jun; 100(6):782-6. PubMed ID: 26396026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose rituximab is effective in pemphigus.
    Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.
    Khanna D; Chong KK; Afifiyan NF; Hwang CJ; Lee DK; Garneau HC; Goldberg RA; Darwin CH; Smith TJ; Douglas RS
    Ophthalmology; 2010 Jan; 117(1):133-139.e2. PubMed ID: 19818507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.